Article thumbnail

Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt

By Peipei Guan, Yi Lu, Jianping Qi, Mengmeng Niu, Ruyue Lian, Fuqiang Hu and Wei Wu

Abstract

The main purpose of this study was to evaluate liposomes containing a bile salt, sodium deoxycholate (SDC), as oral drug delivery systems to enhance the oral bioavailability of the poorly water-soluble and poorly permeable drug, cyclosporine A (CyA). Liposomes composed of soybean phosphatidylcholine (SPC) and SDC were prepared by a thin-film dispersion method followed by homogenization. Several properties of the liposomes including particle size, polydispersity index, and entrapment efficiency were characterized. The in vitro release of CyA from these liposomes was less than 5% at 12 hours as measured by a dynamic dialysis method. The pharmacokinetic results in rats showed improved absorption of CyA in SPC/SDC liposomes, compared with CyA-loaded conventional SPC/cholesterol (Chol) liposomes and microemulsion-based Sandimmune Neoral®. The relative oral bioavailability of CyA-loaded SPC/SDC and SPC/Chol liposomes was 120.3% and 98.6%, respectively, with Sandimmun Neoral as the reference. The enhanced bioavailability of CyA was probably due to facilitated absorption by the liposomes containing SDC rather than improved release rate

Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3124400
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A novel method to prepare highly encapsulated interferon-alpha-2b containing liposomes for intramuscular sustained release.
  2. (2001). Bilosomes: the answer to oral vaccine delivery? Drug Discov Today.
  3. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration.
  4. (2002). Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res.
  5. Chitosan-aprotinin coated liposomes for oral peptide delivery: Development, characterisation and in vivo evaluation.
  6. Combined strategies for liposome characterization during in vitro digestion.
  7. (1997). Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev.
  8. Controlled release of cyclosporin A from liposomes-in-microsphere as an oral delivery systems.
  9. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®) in organ transplantation.
  10. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt.
  11. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts.
  12. (2006). Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm.
  13. (2001). Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev.
  14. Fenofibrate solid dispersion pellets prepared by fluid-bed coating: physical characterization, improved dissolution and oral bioavailability in beagle dogs.
  15. (2008). Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method. Drug Dev Ind Pharm.
  16. Immunosuppressive strategies in transplantation.
  17. (2009). Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloid Surface B.
  18. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization and improved protection against enzymatic degradation.
  19. (2010). Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: Development, characterization, and in vivo evaluation. Drug Deliv.
  20. Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid.
  21. Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin.
  22. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals.
  23. Oral cyclosporine A – the current picture of its liposomal and other delivery systems.
  24. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes).
  25. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes).
  26. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A.
  27. Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and sandimmun neoral.
  28. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles.
  29. Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration.
  30. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®.
  31. Preparation and characterization of calcium pectinate gel beads entrapping catechin-loaded liposomes.
  32. Preparation and characterization of doxorubicin liposomes.
  33. Solubilisation of dipalmitoylphosphatidylcholine bilayers by sodium taurocholate: A model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile salt.
  34. Stability of liposomal formulations: action of amphiphilic molecules.
  35. (2003). Temperature dependence of the interaction of cholate and deoxycholate with fluid model membranes and their solubilization into mixed micelles. Colloid Surface B.
  36. Ultradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes.